Trial Profile
Open Label, Phase II, Study: Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Patients With Stage III/IV Untreated and Relapsed Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Dendritic cell vaccines; Granulocyte macrophage colony stimulating factor; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Lymvac-2
- 24 Feb 2021 Status changed from recruiting to completed.
- 16 Feb 2016 New trial record